| | |
Median OS
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
n
|
(mean ± SD)
|
HR
|
95%CI
|
p-value
|
HR
|
95%CI
|
p-value
|
|---|
|
Age
|
|
<65 years
|
32
|
2122 (2221.6 ± 1725.5)
|
1
|
0.50-4.73
|
0.453
| | | |
|
≥65 years
|
42
|
718 (1071.4 ± 1003.6)
|
1.54
| | | | | |
|
Gender
|
|
Female
|
16
|
767 (1891.9 ± 1536.9)
|
1
|
0.50-12.02
|
0.272
| | | |
|
Male
|
58
|
980 (1479.6 ± 13743.5)
|
2.44
| | | | | |
|
ECOG-PS
|
|
0
|
68
|
1286 (1673.7 ± 1413.1)
|
1
|
0.7021.22
|
0.121
| | | |
|
≥1
|
6
|
302 (379.3 ± 319.4)
|
3.86
| | | | | |
|
NLR
|
|
<2.38
|
51
|
1250.5 (1576.6 ± 1375.0)
|
1
|
1.54-15.23
|
0.007
|
1
|
1.16-18.34
|
0.030
|
|
≥2.38
|
23
|
797.5 (1551.3 ± 1487.5)
|
4.84
| | |
4.62
| | |
|
CPR
|
|
<0.08
|
23
|
1427 (1461.3 ± 1091.4)
|
1
|
1.24-81.27
|
0.030
|
1
|
1.06-110.29
|
0.045
|
|
≥0.08
|
51
|
772 (1617.2 ± 1533.2)
|
10.06
| | |
10.8
| | |
|
LDH
|
|
<158
|
20
|
1286 (1464.7 ± 1205.3)
|
1
|
0.36-4.47
|
0.712
| | | |
|
≥158
|
54
|
808 (1607.3 ± 1565.7)
|
1.27
| | | | | |
|
Neoadjuvant Chemotherapy
|
|
No
|
64
|
1244 (1535.9 ± 1339.8)
|
1
|
0.15-4.10
|
0.772
| | | |
|
Yes
|
10
|
331 (1779.3 ± 2228.4)
|
0.78
| | | | | |
|
Clinical T stage
|
|
≤2
|
38
|
980 (1828.6 ± 1722.9)
|
1
|
0.39-3.47
|
0.781
| | | |
|
≥3
|
36
|
818 (1294.5 ± 1114.1)
|
1.67
| | | | | |
|
Clinical Lymph Node Metastasis
|
|
No
|
70
|
818 (1566.6 ± 1492.3)
|
1
|
0.11-11.57
|
0.921
| | | |
|
Yes
|
4
|
1671 (1607.3 ± 615.3)
|
1.13
| | | | | |
|
Sugical Margin
|
|
Negative
|
68
|
11271.5 (1616.1 ± 1431.6)
|
1
|
0.85-7.74
|
0.095
| | | |
|
Positive
|
6
|
707 (1287.8 ± 2064.0)
|
2.56
| | | | | |
|
Adjuvant chemotherapy
|
|
No
|
49
|
722 (1189.7 ± 1200.8)
|
1
|
0.48-4.52
|
0.493
| | | |
|
Yes
|
25
|
2154 (2311.7 ± 1624.5)
|
1.48
| | | | | |
|
Pathological T stage
|
|
≤2
|
53
|
1112 (1586.9 ± 1466.4)
|
1
|
0.32-3.52
|
0.914
| | | |
|
≥3
|
21
|
982 (1437.4 ± 1603.1)
|
1.07
| | | | | |
|
Pathological Lymph Node Metastasis
|
|
No
|
64
|
1244 (1609.8 ± 1466.4)
|
1
|
1.17-19.17
|
0.030
|
1
|
1.85-82.47
|
0.009
|
|
Yes
|
10
|
718 (1305.9 ± 1523.6)
|
4.73
| | |
12.35
| | |
- OS: overall survival, ECOG-PS: Eastern Cooperative Oncology Group performance status, NLR: neutrophil-to-lymphocyte ration
- CPR: C-reactive protein, LHD: lactate dehydrogenase
